Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours.

British journal of clinical pharmacology - 1 Mar 2011

Gusella Milena, Pasini Felice, Bolzonella Caterina, Meneghetti Silvia, Barile Carmen, Bononi Antonio, Toso Silvia, Menon Daniela, Crepaldi Giorgio, Modena Yasmina, Stievano Laura, Padrini Roberto

Abstract excerpt

AIM: Gemcitabine (GEM) enters normal and tumour cells via concentrative (CNT) and equilibrative nucleoside transporters (ENT) and is subsequently deaminated to the inactive difluorodeoxyurine (dFdU) by cytidine deaminase (CDA). The aim of our study was to ascertain whether the nucleoside transporter genotype and the CDA activity phenotype can predict total GEM plasma clearance. METHODS: Forty-seven patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Antimetabolites, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytidine Deaminase

Share to Deoxycytidine

Share to Gemcitabine

Share to Multivariate Analysis

Share to Neoplasms

Share to White People

Source

Open in PubMed Open full text

Identifiers

PMID: 21284703
DOI: 10.1111/j.1365-2125.2010.03838.x
PMCID: PMC3045553

Genes

GEM
CDA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours.PMID 21284703Read ↗

SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.Semantic proximity Read ↗

Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer.Semantic proximity Read ↗

Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.Semantic proximity Read ↗

Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs.Semantic proximity Read ↗

Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.Semantic proximity Read ↗

Transcription Analysis of Human Equilibrative Nucleoside Transporter-1 Predicts Survival in Pancreas Cancer Patients Treated with GemcitabineSemantic proximity Read ↗

The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C.Semantic proximity Read ↗

CNT1 Expression Influences Proliferation and Chemosensitivity in Drug-Resistant Pancreatic Cancer CellsSemantic proximity Read ↗

Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancerSemantic proximity Read ↗

Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.Semantic proximity Read ↗

Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism.Semantic proximity Read ↗

Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.